

Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028

<https://marketpublishers.com/r/GC74E5040065EN.html>

Date: May 2022

Pages: 240

Price: US\$ 3,300.00 (Single User License)

ID: GC74E5040065EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 Report Highlights:

Global PARP Inhibitors Cancer Therapy Market opportunity: > USD 6 Billion

Commercially Available PARP inhibitors: > 5 Drugs

Comprehensive Clinical Insight On More Than 35 PARP Drug In Clinical Trials

Global PARP Clinical Trials Insight by Company, Country, Indication & Phase

Market Indicators Till 2028

Approved Drugs Dosage, Sales, Patent, Price Insight

Approved Drugs Sales Forecast Till 2028

Global & Regional Market Analysis

Regional Analysis Based On Drug Approvals: US, Europe, China & Japan

Genomic studies have revealed that altered DNA damage response (DDR) is an emerging hallmark and enabling characteristic of cancer, associated with both tumor

initiation and progression. In addition, as anti-cancer cytotoxic agents such as chemotherapy and radiation function to induce DNA damage in cancer cells, alterations in DDR have role in resistance to these therapies. Therefore, scientists believed that targeting of DDR will significantly improve treatment and survival of cancer patients. One prominent DDR family of proteins which is being investigated is poly (ADP-ribose) polymerase (PARP) enzymes which have emerged as potential therapeutic target for the management of cancer.

Scientists have developed several PARP inhibitors which work by binding to the catalytic domain of the PARP enzyme. PARP inhibitors (olaparib, niraparib, rucaparib and talazoparib) are currently approved as a monotherapy by US FDA and EMA. Currently marketed PARP Inhibitors are approved for treating breast cancer, ovarian cancer, fallopian tube cancer; primary peritoneal cancer, and pancreatic cancer. In addition to this, a large number of PARP inhibitors are present in clinical development which is expected to gain approval during the forecast period.

For instance, Senaparib (IMP4297) developed by Impact Therapeutics is an investigational agent which works by targeting PARP (poly-ADP ribose polymerase). The company is currently conducting two phase-1 trials of senaparib in China and Australia. Till date, about 100 patients have been treated with Senaparib and initial results have demonstrated encouraging response. In comparison to other PARP inhibitors currently on the market and in clinical trials; senaparib has a wider therapeutic window and a better safety profile. This potentially makes senaparib more suitable for patients taking the drug chronically such as in maintenance therapy. Moreover, researchers believed that the combination of senaparib with other cancer targeting agents will also demonstrate promising results. Therefore, senaparib has the potential to be the best-in-class PARP inhibitor in the forthcoming years.

Apart from its role as monotherapy, PARP inhibitors have also shown to be promising in combination with other therapeutics including immunotherapy, PI3K, MEK and CDK 4/6 inhibitors. Furthermore, studies have revealed that combining PARP inhibitors with DNA damaging agents including chemotherapy and radiotherapy could prevent repair of treatment induced damage. These approaches have been widely investigated in ovarian and breast cancer. The coming years is expected to witness dominance of combinational therapy in PARP inhibitors market owing to its enhanced efficacy, specificity, and targetability in the management of wide range of cancers.

As per our report findings, the global PARP inhibitor market is expected to surpass US\$ 6 Billion by 2028. Several factors including rising geriatric population with increased risk

of developing cancer, increasing emphasis on research and development, and large number of ongoing clinical trials are the major factors boosting the growth of market. Further, favorable government policies for life science companies and government funding are also expected to boost the PARP inhibitor therapy demand in near future.

The Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 report is a comprehensive analysis of a variety of factors that are prevalent in the PARP Inhibitors. The report provides in-depth analysis on the globally approved PARP inhibitors along with their patent expiration, pricing, dosage, sales analysis, and forecast. It also gives a detailed description of drivers and opportunities in PARP Inhibitor market that helps the consumers and potential customers to get a clear vision and take effective decisions. In addition to this, it comprises various strategic planning techniques, which promotes the way to define and develop the framework of the industries.

Contents

1. INTRODUCTION TO POLY (ADP-RIBOSE) POLYMERASE INHIBITORS

- 1.1 PARP Inhibitors as Unique Cancer Therapy
- 1.2 Evolutionary Aspects of PARP Inhibitors

2. PARP PROTEINS: AN ATTRACTIVE TARGET FOR DEVELOPING CANCER THERAPEUTICS

- 2.1 Structural Organization of Target Site of PARP Inhibitors
- 2.2 Structural Organization of PARP Inhibitors

3. THERAPEUTIC EXPLOITATION OF ROLE OF PARP PROTEINS IN NORMAL CELLS & CANCER CELLS

- 3.1 Significance of PARP Proteins in Normal Cells
- 3.2 Significance of PARP Proteins in Tumorigenesis: Affecting Cell Division & DNA Repair
- 3.3 PARP Inhibitors: Distinct Modes of Action for Eliminating Cancer Cells

4. GLOBAL PARP INHIBITOR MARKET OUTLOOK

- 4.1 Current Market Scenario
- 4.2 Future Market Opportunity

5. PARP INHIBITOR MARKET OPPORTUNITY BY REGION

- 5.1 US
- 5.2 Europe
- 5.3 China
- 5.4 Japan

6. OLAPARIB (LYNPARZA) – 1ST APPROVED PARP INHIBITOR; 2014

- 6.1 Overview
- 6.2 Patent Exclusivity
- 6.3 Pricing & Dosage
- 6.4 Sales Analysis

7. RUCAPARIB (RUBRACA) – 2ND APPROVED PARP INHIBITOR; 2016

- 7.1 Overview
- 7.2 Patent Exclusivity
- 7.3 Pricing & Dosage
- 7.4 Sales Analysis

8. NIRAPARIB (ZEJULA) – 3RD APPROVED PARP INHIBITOR; 2017

- 8.1 Overview
- 8.2 Patent Exclusivity
- 8.3 Pricing & Dosage
- 8.4 Sales Analysis

9. TALAZOPARIB (TALZENNA) – 4TH APPROVED PARP INHIBITOR; 2018

- 9.1 Overview
- 9.2 Patent Exclusivity
- 9.3 Pricing & Dosage

10. FUZULOPARIB (AIRUIYI) - 5TH APPROVED PARP INHIBITOR; 2020

11. PAMIPARIB (PARTRUVIX) – 6TH APPROVED PARP INHIBITOR; 2021

12. PARP INHIBITORS – SALES FORECAST TILL 2028

- 12.1 Lynparza
- 12.2 Rubraca
- 12.3 Zejula
- 12.4 Talzenna

13. APPROVED PARP INHIBITORS REIMBURSEMENT POLICY

- 13.1 Lynparza Reimbursement Policy
- 13.2 Rubraca Reimbursement Policy
- 13.3 Zejula Reimbursement Policy
- 13.4 Talzenna Reimbursement Policy

14. PARP INHIBITOR CLINICAL TRIAL INSIGHT

- 14.1 Company
- 14.2 Country
- 14.3 Indication
- 14.4 Indication

15. GLOBAL POLY(ADP-RIBOSE) POLYMERASE INHIBITORS CLINICAL TRIALS BY COMPANY, INDICATION & PHASE

- 15.1 Preclinical
- 15.2 Phase-I
- 15.3 Phase-I/II
- 15.4 Phase-II
- 15.5 Phase-II/III
- 15.6 Phase-III

16. MARKETED POLY(ADP-RIBOSE) POLYMERASE INHIBITORS CLINICAL INSIGHTS

17. PARP INHIBITORS WITH CONVENTIONAL CANCER THERAPY: EFFICACY & DOSAGE ANALYSIS

- 17.1 PARP Inhibitors with Chemotherapy
 - 17.1.1 Temozolomide
 - 17.1.2 Platinum Salts
 - 17.1.3 Taxanes
 - 17.1.4 Gemcitabine
 - 17.1.5 Topoisomerase inhibitors
- 17.2 PARP Inhibitors in Combination with Radiotherapy

18. IMPROVED EFFICACY OF PARP INHIBITORS BY MODERN CANCER THERAPIES

- 18.1 Combination of PARP Inhibitors & Targeted Therapies
 - 18.1.1 PARP Inhibitors with EGFR Inhibitors
 - 18.1.2 PARP Inhibitors with VEGFR Inhibitors
 - 18.1.3 PARP Inhibitors with PI3K/mTOR Inhibitors
 - 18.1.4 PARP Inhibitors with Trastuzumab

- 18.1.5 Anti-endocrine agents
- 18.1.6 HSP90 Inhibitors
- 18.1.7 IGF-1R & HDAC Inhibitors
- 18.2 PARP Inhibitors in Combination with Immunotherapies

19. GLOBAL PARP INHIBITORS MARKET DYNAMICS

- 19.1 Drivers
- 19.2 Market Challenges

20. PARP INHIBITOR MARKET FUTURE PERSPECTIVE

21. COMPETITIVE LANDSCAPE

- 21.1 2X Oncology
- 21.2 Abbott Laboratories
- 21.3 Allarity Therapeutics
- 21.4 AstraZeneca
- 21.5 BeiGene
- 21.6 Bristol Myers Squibb
- 21.7 Cephalon
- 21.8 Clovis Oncology
- 21.9 Eisai Co. Ltd
- 21.10 GlaxoSmithKline
- 21.11 IMPACT Therapeutics
- 21.12 Jeil Pharmaceuticals
- 21.13 KuDOS Pharmaceuticals
- 21.14 Kyowa Hakko Kirin
- 21.15 Lead Therapeutics
- 21.16 Ono Pharmaceutical
- 21.17 Pfizer

List Of Figures

LIST OF FIGURES

Figure 1-1: Biochemistry & Biological Functions of Poly ADP-Ribosylation Reaction Mediated by Poly (ADP-Ribose) Polymerase (PARP) Enzymes

Figure 1-2: History & Evolution of PARP Inhibitors

Figure 2-1: Structural Organization of PARP-1 & PARP-2 Enzymes

Figure 3-1: PARP Proteins in DNA Damage Repair Mechanism

Figure 3-2: Importance of PARP in DNA Repair Mechanism in Normal Cells

Figure 3-3: Dual Action of PARP inhibition for Cancer Treatment

Figure 4-1: Global – Cancer Incidences & Deaths (Million), 2020

Figure 4-2: Global – PARP Inhibitor Market Size (US\$ Million), 2017-2021

Figure 4-3: Global – PARP Inhibitor Market by Drug Type (US\$ Million), 2021

Figure 4-4: Global – PARP Inhibitor Market by Drug Type (US\$ Million), 2020

Figure 4-5: Global – PARP Inhibitor Market by Drug Type (%), 2021

Figure 4-6: Global – PARP Inhibitor Market by Drug Type (%), 2020

Figure 4-7: Global – PARP Inhibitor Market Size (US\$ Billion), 2022 - 2028

Figure 5-1: US – Cancer Incidences & Deaths (Million), 2020 & 2030

Figure 5-2: US – PARP Inhibitor Market Size (US\$ Million), 2020 & 2021

Figure 5-3: US vs. ROW – PARP Inhibitor Market Size (US\$ Million), 2021

Figure 5-4: US vs. ROW – PARP Inhibitor Market Size (%), 2021

Figure 5-5: US – PARP Inhibitor Market Size (US\$ Million), 2022 - 2028

Figure 5-6: Europe – Cancer Incidences & Deaths (Million), 2020 & 2030

Figure 5-7: Europe – PARP Inhibitor Market Size (US\$ Million), 2020 & 2021

Figure 5-8: Europe vs. ROW – PARP Inhibitor Market Size (US\$ Million), 2021

Figure 5-9: Europe vs. ROW – PARP Inhibitor Market Size (%), 2021

Figure 5-10: Europe – PARP Inhibitor Market Size (US\$ Million), 2022 - 2028

Figure 5-11: China – Cancer Incidences & Deaths (Million), 2020 & 2030

Figure 5-12: China – PARP Inhibitor Market Size (US\$ Million), 2020 & 2021

Figure 5-13: China vs. ROW – PARP Inhibitor Market Size (US\$ Million), 2021

Figure 5-14: China vs. ROW – PARP Inhibitor Market Size (%), 2021

Figure 5-15: China – PARP Inhibitor Market Size (US\$ Million), 2022 - 2028

Figure 5-16: Japan – Cancer Incidences & Deaths (Million), 2020 & 2030

Figure 5-17: Japan – PARP Inhibitor Market Size (US\$ Million), 2020 & 2021

Figure 5-18: Japan – PARP Inhibitor Market Size (US\$ Million), 2022 - 2028

Figure 6-1: US – Olaparib FDA Orphan Designation Year by Indication

Figure 6-2: US – Lynparza FDA Approval Year by Indication

Figure 6-3: Europe – Lynparza EMA Year by Indication

Figure 6-4: Lynparza – Initial Approval Year by Region

Figure 6-5: US – Lynparza Patent by Assignee

Figure 6-6: US – Lynparza Patent Approval & Expiration Year

Figure 6-7: Lynparza – Patent Exclusivity Year by Region

Figure 6-8: US - Cost of Supply of 60 Tablets & Per Unit Cost of Lynparza Oral Tablet (US\$), May'2022

Figure 6-9: US - Cost of Supply of 120 Tablets & Per Unit Cost of Lynparza Oral Tablet (US\$), May'2022

Figure 6-10: UK - Cost of Supply of 56 Tablets & Per Unit Cost of Lynparza Oral Tablet (GBP/US\$), May'2022

Figure 6-11: Lynparza – Recommended Initial & Dose Reductions (mg/day)

Figure 6-12: Lynparza – Cost of Daily & Annual Cost of Treatment (US\$), May'2022

Figure 6-13: Global - Lynparza Annual Sales (US\$ Million), 2018 - 2021

Figure 6-14: US - Lynparza Annual Sales (US\$ Million), 2018 - 2021

Figure 6-15: Europe - Lynparza Annual Sales (US\$ Million), 2018 - 2021

Figure 6-16: ROW - Lynparza Annual Sales (US\$ Million), 2018 - 2021

Figure 6-17: Lynparza - Annual Sales by Region (US\$ Million), 2021

Figure 6-18: Lynparza - Annual Sales by Region (%), 2021

Figure 6-19: Global - Lynparza Quarterly Sales (US\$ Million), 2021

Figure 6-20: Global - Lynparza Quarterly Sales (US\$ Million), 2020

Figure 7-1: US – Rucaparib FDA Orphan Designation & Patent Exclusivity Year

Figure 7-2: US – Rubraca FDA Approval Year by Indication

Figure 7-3: Rubraca - Approval Year by Region

Figure 7-4: US – Lynparza Patent Approval & Expiration Year

Figure 7-5: US - Cost of Supply of 60 Tablets & Per Unit Cost of Rubraca Oral Tablet (US\$), May'2022

Figure 7-6: Europe - Cost of Supply of 60 Tablets & Per Unit Cost of Rubraca 200mg Oral Tablet (Euro/US\$), May'2022

Figure 7-7: Europe - Cost of Supply of 60 Tablets & Per Unit Cost of Rubraca 300mg Oral Tablet (Euro/US\$), May'2022

Figure 7-8: Rubraca – Recommended Initial & Dose Reductions (mg/day)

Figure 7-9: Rubraca – Recommended Maximum & Minimum Dose (mg/day)

Figure 7-10: Rubraca – Cost of Daily & Annual Cost of Treatment (US\$), May'2022

Figure 7-11: Global - Rubraca Annual Sales (US\$ Million), 2018 - 2021

Figure 7-12: US - Rubraca Annual Sales (US\$ Million), 2018 - 2021

Figure 7-13: Europe - Rubraca Annual Sales (US\$ Million), 2019 - 2021

Figure 7-14: Rubraca - Annual Sales by Region (US\$ Million), 2021

Figure 7-15: Rubraca - Annual Sales by Region (%), 2021

Figure 7-16: Rubraca - Annual Sales by Region (US\$ Million), 2020

- Figure 7-17: Rubraca - Annual Sales by Region (%), 2021
- Figure 7-18: Global - Rubraca Quarterly Sales (US\$ Million), 2021
- Figure 7-19: US - Rubraca Quarterly Sales (US\$ Million), 2021
- Figure 7-20: Europe - Rubraca Quarterly Sales (US\$ Million), 2021
- Figure 8-1: US – Niraparib FDA Orphan Designation & Patent Exclusivity Year
- Figure 8-2: US – Zejula FDA Approval Year by Ovarian Cancer Subtypes
- Figure 8-3: Zejula – Initial Approval Year by Region
- Figure 8-4: US – Zejula Patent Approval & Expiration Year
- Figure 8-5: China – Zejula Patent Expiration Year
- Figure 8-6: US - Cost of Supply of 30 Capsules & Per Unit Cost of Zejula Oral Capsules (US\$), May'2022
- Figure 8-7: US - Cost of Supply of 90 Capsules & Per Unit Cost of Zejula Oral Capsules (US\$), May'2022
- Figure 8-8: UK - Cost of Supply of 84, 56 Capsules & Per Unit Cost of Zejula Oral Capsule (GBP/US\$), May'2022
- Figure 8-9: Zejula – Recommended Initial Dose by Weight (mg/day)
- Figure 8-10: Zejula – Recommended Initial & Dose Reductions (mg/day)
- Figure 8-11: Zejula – Recommended Maximum & Minimum Dose (mg/day)
- Figure 8-12: Zejula – Cost of Daily & Annual Cost of Treatment (US\$), May'2022
- Figure 8-13: Global - Zejula Annual Sales (Euro/US\$ Million), 2019 - 2021
- Figure 8-14: US - Zejula Annual Sales (Euro/US\$ Million), 2019 - 2021
- Figure 8-15: Europe - Zejula Annual Sales (Euro/US\$ Million), 2019 - 2021
- Figure 8-16: ROW - Zejula Annual Sales (Euro/US\$ Million), 2020 & 2021
- Figure 8-17: Zejula - Annual Sales by Region (Euro/US\$ Million), 2021
- Figure 8-18: Zejula - Annual Sales by Region (%), 2021
- Figure 8-19: Global - Zejula Quarterly Sales (Euro/US\$ Million), 2021
- Figure 8-20: US - Zejula Quarterly Sales (Euro/US\$ Million), 2021
- Figure 8-21: ROW - Zejula Quarterly Sales (Euro/US\$ Million), 2021
- Figure 9-1: Talzenna – Approval Year by Region
- Figure 9-2: US – Talzenna Patent Approval & Expiration Year
- Figure 9-3: US – Talzenna Patent by Assignee
- Figure 9-4: US - Cost of Supply of 30 Capsules & Per Unit Cost of Talzenna 0.25mg Oral Capsules (US\$), May'2022
- Figure 9-5: US - Cost of Supply of 30 Capsules & Per Unit Cost of Talzenna 0.5mg, 0.75mg, & 1mg Oral Capsules (US\$), May'2022
- Figure 9-6: UK - Cost of Supply of 30 Capsules & Per Unit Cost of Talzenna 0.25mg Oral Capsule (GBP/US\$), May'2022
- Figure 9-7: UK - Cost of Supply of 30 Capsules & Per Unit Cost of Talzenna 1mg Oral Capsule (GBP/US\$), May'2022

- Figure 9-8: Talzenna – Recommended Initial & Dose Reductions (mg/day)
- Figure 9-9: Talzenna – Recommended Maximum & Minimum Dose (mg/day)
- Figure 9-10: Talzenna – Cost of Daily & Annual Cost of Treatment (US\$), May'2022
- Figure 10-1: Fuzuloparib – Recommended Maximum & Minimum Dose (mg/day)
- Figure 11-1: China – Partruvix Priority Review & NMPA Approval Year
- Figure 12-1: Global – Lynparza Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 12-2: US – Lynparza Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 12-3: Europe – Lynparza Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 12-4: ROW – Lynparza Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 12-5: Global – Rubraca Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 12-6: US – Rubraca Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 12-7: Europe – Rubraca Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 12-8: Global – Zejula Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 12-9: US – Zejula Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 12-10: Europe – Zejula Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 12-11: ROW – Zejula Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 12-12: Global – Talzenna Estimated Sales Value (US\$ Million), 2022 - 2028
- Figure 13-1: Lynparza - Total Treatment Cost & Reimbursement Cost (US\$)
- Figure 13-2: Lynparza – In Pocket & Out of Pocket Cost of Treatment (%)
- Figure 13-3: Rubraca - Total Treatment Cost & Reimbursement Cost (US\$)
- Figure 13-4: Rubraca – In Pocket & Out of Pocket Cost of Treatment (%)
- Figure 13-5: Zejula - Total Treatment Cost & Reimbursement Cost (US\$)
- Figure 13-6: Zejula – In Pocket & Out of Pocket Cost of Treatment (%)
- Figure 13-7: Zejula - Total Treatment Cost & Reimbursement Cost (US\$)
- Figure 13-8: Zejula – In Pocket & Out of Pocket Cost of Treatment (%)
- Figure 14-1: Global - PARP Inhibitor Drugs in Clinical Trials by Company, 2022 till 2028
- Figure 14-2: Global - PARP Inhibitor Drugs in Clinical Trials by Country, 2022 till 2028
- Figure 14-3: Global - PARP Inhibitor Drugs in Clinical Trials by Indication, 2022 till 2028
- Figure 14-4: Global - PARP Inhibitor Drugs in Clinical Trials by Phase, 2022 till 2028
- Figure 17-1: Tolerable Dosage of Rucaparib & Temozolomide Combination Therapy in Clinical Trials for Advanced Malignancy (mg/m²)
- Figure 17-2: Study of Veliparib + Temozolomide Showing Improved Survival of Patients with Metastatic Melanoma (Months)
- Figure 17-3: Estimated Glioblastoma Treatment Cost for Temozolomide + PARP Inhibitor Therapy, (US\$/Cycle)
- Figure 17-4: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (mg/Day & mg/m²/Day)
- Figure 17-5: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (Administration/Cycle)

Figure 17-6: Olaparib & Paclitaxel Combination Therapy Cost Analysis for Metastatic Gastric Cancer (US\$/Cycle)

Figure 17-7: Overall Survival in Patients with Triple-Negative Breast Cancer Treated with Gemtacin & Carboplatin Chemotherapy vs. Combination Therapy with Iniparib (Months)

I would like to order

Product name: Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/GC74E5040065EN.html>

Price: US\$ 3,300.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC74E5040065EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970